Media stories about Prothena Co. PLC (NASDAQ:PRTA) have been trending somewhat positive this week, AlphaOne Sentiment reports. AlphaOne, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Prothena Co. PLC earned a daily sentiment score of 0.24 on AlphaOne’s scale. AlphaOne also gave news coverage about the company an impact score of 37 out of 100, indicating that recent news coverage is unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s analysis:
- PLC (PRTA) Now Covered by Piper Jaffray Companies (graffiotech.com)
- Prothena Co. PLC (PRTA) Sees Significant Decline in Short Interest (americanbankingnews.com)
- Prothena Co. PLC (PRTA) Research Coverage Started at Cantor Fitzgerald (americanbankingnews.com)
- Analysts Expect Prothena Co. PLC (PRTA) Will Announce Earnings of -$1.31 Per Share (americanbankingnews.com)
- Oppenheimer Holdings Inc. Analysts Give Prothena Co. PLC (PRTA) a $70.00 Price Target (americanbankingnews.com)
Several equities research analysts recently weighed in on the stock. Instinet assumed coverage on shares of Prothena Co. PLC in a research report on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Prothena Co. PLC in a research report on Wednesday. They issued an “overweight” rating and a $86.00 price target on the stock. Zacks Investment Research upgraded shares of Prothena Co. PLC from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Tuesday, January 3rd. Nomura assumed coverage on shares of Prothena Co. PLC in a research report on Wednesday, March 1st. They issued a “buy” rating on the stock. Finally, Oppenheimer Holdings Inc. restated a “buy” rating on shares of Prothena Co. PLC in a research report on Wednesday, March 22nd. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $74.73.
Prothena Co. PLC (NASDAQ:PRTA) traded up 3.81% on Thursday, reaching $52.54. 371,743 shares of the company’s stock traded hands. The stock’s market capitalization is $1.84 billion. Prothena Co. PLC has a 52 week low of $33.53 and a 52 week high of $68.18. The firm has a 50-day moving average price of $53.81 and a 200-day moving average price of $53.96.
Prothena Co. PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, February 14th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by $0.29. Prothena Co. PLC had a negative net margin of 11,365.41% and a negative return on equity of 32.65%. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter last year, the business earned ($0.76) EPS. The company’s quarterly revenue was down 35.5% on a year-over-year basis. On average, analysts predict that Prothena Co. PLC will post ($5.10) earnings per share for the current year.
In other news, CFO Tran Nguyen acquired 1,000 shares of Prothena Co. PLC stock in a transaction that occurred on Thursday, March 9th. The stock was purchased at an average cost of $51.32 per share, with a total value of $51,320.00. Following the purchase, the chief financial officer now owns 3,200 shares in the company, valued at $164,224. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $55.86, for a total value of $195,510.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $354,431.70. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Prothena Co. PLC (PRTA) Given Media Impact Rating of 0.24” was first posted by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at http://sleekmoney.com/prothena-co-plc-prta-given-media-impact-rating-of-0-24/1739612.html.
About Prothena Co. PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/prothena-co-plc-prta-given-media-impact-rating-of-0-24/1739612.html
Receive News & Ratings for Prothena Co. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Co. PLC and related companies with MarketBeat.com's FREE daily email newsletter.